Analysts Expect TherapeuticsMD Inc (TXMD) Will Post Earnings of -$0.09 Per Share
Wall Street analysts predict that TherapeuticsMD Inc (NASDAQ:TXMD) will post ($0.09) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have made estimates for TherapeuticsMD’s earnings. The lowest EPS estimate is ($0.11) and the highest is ($0.07). TherapeuticsMD posted earnings per share of ($0.11) in the same quarter last year, which would indicate a positive year-over-year growth rate of 18.2%. The business is scheduled to issue its next earnings results on Tuesday, May 1st.
On average, analysts expect that TherapeuticsMD will report full-year earnings of ($0.38) per share for the current year, with EPS estimates ranging from ($0.69) to $0.18. For the next financial year, analysts expect that the business will post earnings of ($0.05) per share, with EPS estimates ranging from ($0.35) to $0.24. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for TherapeuticsMD.
TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Tuesday, February 20th. The company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.01). TherapeuticsMD had a negative return on equity of 63.67% and a negative net margin of 458.49%. The business had revenue of $4.13 million during the quarter, compared to analyst estimates of $4.66 million. During the same quarter in the prior year, the company earned ($0.12) EPS. The company’s revenue was down 8.0% on a year-over-year basis.
TherapeuticsMD (NASDAQ TXMD) traded down $0.06 during trading on Friday, hitting $5.22. 372,896 shares of the stock were exchanged, compared to its average volume of 1,880,363. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30. The company has a market cap of $1,157.95, a P/E ratio of -13.74 and a beta of 1.36.
Institutional investors have recently made changes to their positions in the business. Candriam Luxembourg S.C.A. grew its holdings in TherapeuticsMD by 10.4% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 530,000 shares of the company’s stock worth $2,804,000 after acquiring an additional 50,000 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in TherapeuticsMD by 26.6% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 142,930 shares of the company’s stock worth $756,000 after acquiring an additional 30,030 shares during the last quarter. Swiss National Bank grew its holdings in TherapeuticsMD by 12.3% in the 3rd quarter. Swiss National Bank now owns 289,800 shares of the company’s stock worth $1,533,000 after acquiring an additional 31,800 shares during the last quarter. State Street Corp grew its holdings in TherapeuticsMD by 14.9% in the 2nd quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after acquiring an additional 583,094 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in TherapeuticsMD in the 3rd quarter worth $528,000. 73.28% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Analysts Expect TherapeuticsMD Inc (TXMD) Will Post Earnings of -$0.09 Per Share” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/03/14/analysts-expect-therapeuticsmd-inc-txmd-will-post-earnings-of-0-09-per-share.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.